相关临床试验
97
24 进行中
药物批准
49
批准总数
监管机构
1
监管机构数
成立时间
N/A
进行中（未招募）
21
21.6%
已完成
59
60.8%
尚未招募
3
3.1%
招募中
3
3.1%
撤回
11
11.3%
- Raymond Rodriguez-Torres, a biotech leader with over two decades of experience at Genentech, Roche, and Sanofi-Aventis, has been unanimously appointed President of First Ascent Biomedical. - His leadership will focus on scaling the company's xDRIVE platform, which integrates ex vivo drug sensitivity testing, genomic analysis, and AI to guide personalized cancer treatment decisions. - The platform has been prospectively validated across 52 cancer types and published in Nature Medicine, representing the first clinical application of Functional Precision Oncology to achieve this milestone. - Rodriguez-Torres also serves as Chairman of the Live Like Bella Childhood Cancer Foundation, bringing a personal commitment shaped by his daughter's legacy in pediatric cancer advocacy.
- The STAMPEDE trial found that adding metformin to standard care for 1,874 non-diabetic men with metastatic prostate cancer did not significantly improve overall survival (HR 0.91, 95% CI: 0.80-1.03, P = 0.15). - Metformin demonstrated significant metabolic benefits, with patients gaining less than half the weight of controls (2kg vs 4.4kg after two years) and showing improved cholesterol and blood sugar levels. - The drug was well-tolerated with diarrhea as the main side effect, and showed potential anti-cancer benefits in the highest-risk patient subgroup, though this finding was not statistically powered for definitive conclusions. - These metabolic improvements may help mitigate the adverse effects of androgen deprivation therapy and reduce cardiovascular risks in prostate cancer patients with extended survival.
- The global protein therapeutics market reached an estimated $400 billion in value, driven by increasing pharmaceutical company investment in advanced protein-based drug development strategies. - Nearly 20 protein-based drugs received regulatory approval in 2023 for treating various diseases including cancer and metabolic disorders, demonstrating accelerated development in this therapeutic area. - Monoclonal antibodies dominate the protein therapeutics sector with an estimated market value of $48.5 billion by 2011, representing the largest segment ahead of insulin therapies. - The protein therapeutics market is projected to grow at a compound annual growth rate of approximately 13% during 2012-2014, significantly outpacing overall pharmaceutical market growth.
- Tevogen Bio announced plans to expand TVGN 489's target population to include patients aged 65 and older, building on previous specialty care pipeline projections of nearly $1 billion in launch year revenue. - The expansion comes as the U.S. reports cases of the new COVID variant NB.1.8.1, with the company prioritizing clinical manufacturing capacity to address unmet medical needs. - TVGN 489's comprehensive pipeline targets SARS-CoV-2 infections across multiple patient populations including cancer patients, autoimmune disease patients, and Long COVID sufferers. - The company's ExacTcell platform supports the expanded pipeline, with updated revenue forecasts and risk-adjusted net present value calculations to follow.
- The U.S. District Court ordered Teva Pharmaceuticals to remove its ProAir HFA inhaler device patents from the FDA's Orange Book, ruling they don't meet statutory listing requirements. - The Federal Circuit affirmed that patents must claim the drug's active ingredient to be Orange Book listable, rejecting Teva's argument that device component patents qualify. - The case, sparked by Amneal Pharmaceuticals' generic challenge, has drawn attention from major pharma companies and the FTC, potentially impacting future drug-device patent listings.
- The FDA has granted approval to insulin-aspart-szjj (Merilog), marking the first rapid-acting insulin biosimilar for diabetes treatment, expanding treatment options for over 38 million Americans with diabetes. - Developed by Sanofi-Aventis as a biosimilar to Novo Nordisk's Novolog, Merilog is indicated for glycemic control in both adult and pediatric diabetes patients, available in pre-filled pens and multiple-dose vials. - The approval represents FDA's ongoing commitment to increase access to affordable insulin options, joining two previously approved long-acting insulin biosimilars from 2021.
- Minimal Residual Disease (MRD) testing offers a sensitive method for detecting remaining cancer cells, influencing treatment decisions and improving patient outcomes in multiple myeloma. - The FDA's ODAC is considering MRD as a surrogate endpoint for drug approval, signaling a shift towards MRD negativity as a primary goal in clinical trials. - Studies like CEPHEUS, with MRD negativity as the primary endpoint, highlight the increasing importance of achieving and sustaining MRD negativity for better progression-free survival. - Sustained MRD negativity, particularly for 12 months or longer, significantly reduces the risk of disease progression or death in newly diagnosed multiple myeloma patients.
